A5102003784- Neuroscience and Neuropharmacology Research
- Cannabis and Cannabinoid Research
- Neurotransmitter Receptor Influence on Behavior
- Parkinson's Disease Mechanisms and Treatments
- Ubiquitin and proteasome pathways
- Retinoids in leukemia and cellular processes
- Biliary and Gastrointestinal Fistulas
- Monoclonal and Polyclonal Antibodies Research
- Endoplasmic Reticulum Stress and Disease
- Pancreatitis Pathology and Treatment
- Neurological disorders and treatments
- Amoebic Infections and Treatments
- Sleep and Wakefulness Research
- Hepatitis B Virus Studies
- Peroxisome Proliferator-Activated Receptors
- Rheumatoid Arthritis Research and Therapies
- Adipose Tissue and Metabolism
- Cell death mechanisms and regulation
- Neuroscience of respiration and sleep
The University of Texas Health Science Center at San Antonio
2009-2020
Trinity University
2014
The University of Texas System
2009-2012
University of California, San Diego
2006
Abstract Parkinson’s disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail prevent or slow down progression. In this study, we investigated molecular mechanisms which non‐selective cannabinoid receptor agonist WIN55,212‐2 (WIN) protects mouse from 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced neurotoxicity...
Abstract Amantadine and dextromethorphan suppress levodopa (L‐DOPA)‐induced dyskinesia (LID) in patients with Parkinson’s disease (PD) abnormal involuntary movements (AIMs) the unilateral 6‐hydroxydopamine (6‐OHDA) rat model. These effects have been attributed to N ‐methyl‐ d ‐aspartate (NMDA) antagonism. However, amantadine are also thought block serotonin (5‐HT) uptake cause 5‐HT overflow, leading stimulation of 1A receptors, which has shown reduce LID. We undertook a study 6‐OHDA rats...
Social withdrawal in the sub-chronic phencyclidine (PCP) rat model, a behavioral correlate of negative symptoms schizophrenia, results from deficits brain endocannabinoid transmission. As cannabis intake has been shown to affect negatively course and expression psychosis, we tested whether beneficial effects endocannabinoid-mediated CB1 activation on social PCP-treated rats (5 mg/kg, twice daily for 7 days)also occurred after administration Δ9-tetrahydrocannabinol (THC; 0.1, 0.3, 1.0 i.p.)....